Startups
CEVR is a leader on issues pertaining to value, cost-effectiveness, and risk tradeoffs in health care decisions. We inform national clinical and public health policy issues through our analysis of the benefits, risks and costs of strategies to improve health and health care. Our organization is a member of the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, Boston. We undertake scientific research projects, advance methods development for the field, train the next generation of practitioners and users, and work with policymakers worldwide to develop reasoned policy solutions.
Overview
Location
United States, Massachusetts, Boston
Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 8, 2025 | Study Shows Critical Misalignment Between Health Plan Utilization Management & Clinical Guidelines for Specialty Drugs | Data from NPC and CEVR reveal utilization management is common even when clinical guidelines do not support its use. WASHINGTON, DC, UNITED STATES, July 8, 2025 /EINPresswire.com/ -- New research by the National Pharmaceutical Council (NPC)... |
| Dec 3, 2021 | Massachusetts Legislature Proposes Banning Use Of Cost-Effectiveness Analysis To Inform Healthcare Coverage Decisions | Highway Signpost "Cost-Effectiveness Analysis"getty |
| May 7, 2021 | Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it | A key element in the long-simmering debate on reining in drug prices in the United States is how to ensure that prices are affordable, represent a sufficient reward to industry for the innovation it provides, and reflect the benefit that pa... |
| Nov 14, 2019 | Working with ICER, or around it, on cost-effectiveness estimates | As the national debate over prescription drug pricing reaches a fever pitch, drug manufacturers bringing new products to market face unique challenges. From the threats of political oversight and media scrutiny to academic guesstimates on t... |
| Feb 22, 2019 | The U.S. shouldn’t use the ‘QALY’ in drug cost-effectiveness reviews | What’s a year of life worth? That question is at the heart of a metric called the quality-adjusted life year that is increasingly being used to make decisions about paying for new drugs. If I was asked that question about one of my children... |
Reviews 0
FAQ about CEVR
What has the press written about CEVR?
Parsers VC has collected 6 articles mentioning CEVR, among them “Study Shows Critical Misalignment Between Health Plan Utilization Management & Clinical Guidelines for Specialty Drugs” (Jul 8, 2025) and “Massachusetts Legislature Proposes Banning Use Of Cost-Effectiveness Analysis To Inform Healthcare Coverage Decisions” (Dec 3, 2021).
Is CEVR still active?
Yes, CEVR is active; its latest activity on Parsers VC dates from Mar 2, 2026.